Stock Analysis

Chia Tai Enterprises International Full Year 2023 Earnings: EPS: US$0.01 (vs US$0.026 loss in FY 2022)

Source: Shutterstock

Chia Tai Enterprises International (HKG:3839) Full Year 2023 Results

Key Financial Results

  • Revenue: US$174.0m (up 9.3% from FY 2022).
  • Net income: US$2.55m (up from US$6.68m loss in FY 2022).
  • Profit margin: 1.5% (up from net loss in FY 2022). The move to profitability was driven by higher revenue.
  • EPS: US$0.01 (up from US$0.026 loss in FY 2022).
SEHK:3839 Earnings and Revenue History February 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chia Tai Enterprises International shares are down 5.3% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Chia Tai Enterprises International (1 is concerning!) that you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Chia Tai Enterprises International is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:3839

Chia Tai Enterprises International

Chia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally.

Mediocre balance sheet and slightly overvalued.